CIRIN is continuing its drive to widen its product line - stregthening its position in several theurapautic classes in each quarter. Esopase is 2nd of the five launches planned for 2008. It follows Plasmocide Plus and is perhaps one of the most promissing one for the company. 
No comments:
Post a Comment